Form 4: Prothena Corp Public Ltd Co: Director Dennis J. Selkoe Reports Stock Option Grant

Director Dennis J. Selkoe reports the acquisition of stock options for 20,183 ordinary shares of Prothena Corp Public Ltd Co.

Summary

• On May 14, 2025, Dennis J. Selkoe, a director of Prothena Corp Public Ltd Co, was granted stock options to purchase 20,183 ordinary shares.
• The exercise price of the stock options is $6.885 per share.
• The options vest 100% on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026, assuming continuous service as a director.
• The expiration date for these options is May 14, 2035.
• Following this transaction, Selkoe directly owns 20,183 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant, which is generally neutral. It indicates continued alignment of the director with the company's interests.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparing Prothena's director compensation structure with peers like Biogen or Ionis Pharmaceuticals would provide further context on the competitiveness of their compensation packages.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholders by aligning the director's interests with the company's long-term performance.

Key Dates

Keywords

stock options, Form 4, director, Prothena, PRTA, beneficial ownership, securities